New topics TransChromosomics

2020.07.17

A group of associate professor Yasuhiro Kazuki of Chromosome Engineering Research Center of Tottori University, collaborator of Trans Chromosomics, Inc., succeeded in producing a mouse model of Down syndrome and published a paper.

2020.07.10

Trans Chromosomics, Inc. signed a joint research agreement with Otsuka Pharmaceutical Co., Ltd. for the production of fully human antibodies.

2020.03.17

Trans Chromosomics, Inc. concludes a research agreement with Precision Antibody with respect to development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing mice.

2020.03.04

Trans Chromosomics, Inc. signed a feasibility research agreement with Shionogi & Co., Ltd. for antibody production using fully human antibody-producing mice.

2020.03.04

Trans Chromosomics, Inc. concludes a tripartite research agreement with Japan’s National Institute of Infectious Diseases and Tottori University with respect to development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing mice.

2020.02.27

Development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing animals

2019.05.07

Trans Chromosomics, Inc. concludes a joint research agreement with Japan's National Institute of Infectious Diseases with respect to development of human antibodies against pathogenic viruses by utilizing fully human antibody-producing animals.
 

2019.05.07

Trans Chromosomics, Inc. concludes a tripartite research agreement with Japan's National Institute of Infectious Diseases and Tottori University with respect to development of human antibodies against pathogenic viruses and toxins by utilizing fully human antibody-producing animals.

2019.02.20

Trans Chromosomics, Inc. Announces Changes in Top Management.

2018.12.01

Trans Chromosomics, Inc. established the Board of Corporate Auditors.

2018.06.14

Trans Chromosomics, Inc. has Signed MTA with NIH/NIAMS on Fully Human Monoclonal Antibody Producing Mice.

2018.04.24

Attending at 2018 BIO International Convention (Exhibition & Partnering)

2018.01.31

Trans Chromosomics, Inc. Announces Changes in Top Management

2017.11.03

Trans Chromosomics, Inc. Has Signed Feasibility Research Collaboration Agreement with Mitsubishi Tanabe Pharma On Fully Human Monoclonal Antibody Producing Mice/Rats.

 

2017.03.30
Trans Chromosomics, Inc. Has Signed Feasibility Research Collaboration Agreement Including Option Rights with KAN Research Institute Inc. And Eisai Co., Ltd. On Fully Human Monoclonal Antibody Producing Mice/Rats.

 

2017.03.15 

Trans Chromosomics Inc. Has Signed Feasibility Research Collaboration Agreement with Daiichi Sankyo On Fully Human Monoclonal Antibody Producing Mice/Rats

2016.06.22 

English site is available now!!

Our Mission

We contribute to people's living and health by

applying innovative chromosome engineering

technology developed by Tottori University (Japan) to medical treatment and drug discovering widely

Memoirs of the science

Trans Chromosomics, Inc.

 トランスクロモソミックス

 

© 2020 by Trans Chromosomics, Inc. Proudly created with Wix.com

This site was designed with the
.com
website builder. Create your website today.
Start Now